While inhibition of either Th1-type cytokine is an effective monotherapy in experimental IBD [39], preclinical data also support the role of IFN-γ/TNF-α cooperativity (if not synergy) in IBD immunopathology [40]. The gene discussed is TNF; the disease is inflammatory bowel disease.